Elsevier

Progress in Neurobiology

Volume 85, Issue 4, August 2008, Pages 407-432
Progress in Neurobiology

Emerging restorative treatments for Parkinson's disease

https://doi.org/10.1016/j.pneurobio.2008.05.001Get rights and content

Abstract

Several exciting approaches for restorative therapy in Parkinson's disease have emerged over the past two decades. This review initially describes experimental and clinical data regarding growth factor administration. We focus on glial cell line-derived neurotrophic factor (GDNF), particularly its role in neuroprotection and in regeneration in Parkinson's disease. Thereafter, we discuss the challenges currently facing cell transplantation in Parkinson's disease and briefly consider the possibility to continue testing intrastriatal transplantation of fetal dopaminergic progenitors clinically. We also give a more detailed overview of the developmental biology of dopaminergic neurons and the potential of certain stem cells, i.e. neural and embryonic stem cells, to differentiate into dopaminergic neurons. Finally, we discuss adult neurogenesis as a potential tool for restoring lost dopamine neurons in patients suffering from Parkinson's disease.

Introduction

Almost 20 years ago, the first successful cell transplantation trials in Parkinson's disease (PD) patients promoted the view that the damaged brain can be repaired by replacing lost neurons (Lindvall et al., 1990). Over the last decade, new discoveries have indicated that the adult human brain has the potential to generate its own new neurons, and that therefore the adult brain is much more plastic than was initially believed (Curtis et al., 2007, Eriksson et al., 1998). Furthermore, the concomitant exploration of several growth factors with neurotrophic capacity, and demonstration that they can promote regrowth of damaged neural connections, have reinforced the view that the adult brain may be amenable to restorative therapies. The idea that adult neurogenesis can be controlled and manipulated to restore lost dopaminergic neurons in the brains of PD patients has attracted recent attention. Meanwhile, another aspect of stem cell research has focused on regenerative medicine, based on attempting to restore lost cells and tissues in the human body by grafting stem cells or their progeny.

The future outlook for existing PD therapies has been reviewed by Singh et al. (2007). Current therapies for PD are primarily based on pharmacological replacement of lost striatal dopamine. Dopamine replacement can be achieved through administration of the dopamine precursor l-dopa, direct activation of the dopamine receptor by agonists, or by augmentation of the remaining dopaminergic neurotransmission through inhibition of dopamine-degrading enzymes. These approaches have achieved remarkable relief of PD symptoms. However, none lead to complete dopamine restoration or marked neuroprotection of the remaining dopaminergic neurons, and long-term drug administration can result in side effects related to disease progression. In advanced disease, the vast majority of patients experience fluctuations in response to medication, a phenomenon known as the “on–off” effect. Patients are able to move during the “on” period, whereas they are immobile during the “off” period. After a few years of drug treatment, most patients exhibit multiple “off” periods every day. In addition, patients may suffer from l-dopa-induced dyskinesias, typically during “on” periods or when they transition from “on” to “off”. Patients with this complication can be successfully treated with deep brain stimulation, mainly targeting the subthalamic nucleus. These operations can partially normalize abnormal neural activity in the subthalamic-pallidum connections, which drives some of the symptoms.

Regardless of the known side effects, pharmacological dopamine replacement remains an important therapy, which illustrates the fundamental centrality of the nigrostriatal dopamine system to the symptomatology of PD. Indeed, much would be gained if these neurons could be restored or replaced in the brains of PD patients. The successful transplantation of embryonic mesencephalic cells into the striatum of patients with PD in the late 1980s raised hopes that it may be possible not only to halt progression, but also to actually reverse the disease. The shortage of suitable embryonic donor tissue is a major limiting factor that precludes use of this cell therapy as a general therapy for PD. In addition, results from animal studies indicate that only roughly 10% of these cells survive transplantation (Brundin et al., 2000a). Based on this considerable cell death, and the fact that only few dopaminergic precursors are present in the donor tissue to begin with, enrichment of dopaminergic neurons prior to transplantation would be valuable. Thus, there is an unmet need for a means of generating a large pool of dopaminergic precursors or neurons for use in transplantation procedures.

In this review, we discuss various approaches to restorative therapy in PD (Fig. 1). Some, such as the viral vector-mediated delivery of dopamine-synthesizing enzymes, are based on restoring the neurochemistry of the striatum (Carlsson et al., 2007, Singh et al., 2007). However, in this review we do not discuss attempts to directly restore neurotransmitter-synthesizing enzymes further. Instead we focus on therapies that promote structural and cellular restoration of the basal ganglia in PD patients. These therapies are primarily applicable to patients in which conventional pharmacotherapy has begun to fail. We describe them in order of the PD stages to which they are relevant, as the disease progresses from moderate to severe. Hence, we will first discuss neuroprotection/restoration of the diseased nigrostriatal dopamine system by growth factor delivery, particularly delivery of glial cell line-derived neurotrophic factor (GDNF). When the diseased nigral dopaminergic neurons in the PD brain are beyond rescue, cell transplantation is an option to restore lost neurons. In the next section, we will therefore cover cell transplantation and briefly describe key animal experiments, as well as available clinical data regarding fetal cell transplantation. In the subsequent section, we will describe the developmental biology of dopaminergic neurons, and the characteristics of different stem cells used to generate dopaminergic neurons for transplantation purposes. We focus on the various approaches utilized to differentiate these stem cells into dopaminergic neurons. In the final section, we will cover neurogenesis in the adult brain as a hypothetical strategy to restore dopaminergic neurons in PD patients.

Section snippets

Growth factor delivery in the brain

In this section, we review the use of several well-known growth factors used in both preclinical studies and clinical trials. We pay special attention to GDNF and its protective and restorative effect on the dopamine-depleted striatum. This molecule has been studied extensively in experimental models of PD for more than a decade. First, we provide an overview of the beneficial effects of growth factors on degenerating dopaminergic neurons. Further, we discuss various strategies for growth

Cell transplantation therapy for Parkinson's disease

The successful transplantation of immature dopaminergic neurons in animal models of PD spurred clinical trials in patients starting in the mid-1980s. In a short section, we describe some key animal experiments relevant to clinical trials, and recent developments regarding the grafting of stem cell-derived dopaminergic neurons. We then briefly describe results obtained in open-label clinical trials during the 1990s, and compare them to those derived from two major controlled trials that have

Stem cells as a source for dopamine cell transplantation

For a successful cell-based therapy for PD, knowledge about the developmental stage and identity of the transplanted cells are crucial to obtain optimal integration and survival of the graft in the host brain. In the initial section, we introduce the relevant developmental biology, i.e. how a stem cell in the midbrain can become a dopaminergic neuron. In the following sections we describe different sources of stem cells that might be used to generate dopaminergic neurons, i.e. neural and

Neurogenesis in the human brain

During the last decade, neurogenesis has been confirmed in two regions in the human brain: the hippocampal subgranular zone (SGZ) in the dentate gyrus and the subventricular zone (SVZ) lining the lateral ventricles (Curtis et al., 2007, Eriksson et al., 1998). These two neurogenic regions have been extensively studied in the rodent brains. The neuroblasts originating from the SVZ migrate via the rostral migratory stream to the olfactory bulb where they mature into region specific neurons and

Conclusion

In this review, we highlight the varying aspects of both experimental research and clinical approaches currently being undertaken for restorative treatment of PD. Some of these therapies, when eventually developed to their full potential, may not only halt the progression of the disease, but also give the patient back functions already lost. The most clinically driven approach currently being investigated is the delivery of growth factors from the GDNF family. Many approaches are being tested

Acknowledgements

Swedish Research Council, Tore Nilson's Foundation, PROMEMORIA (EU 6th FP), NeuroNe (EU 6th FP), Magnus Bergvall's Foundation, STEMS (EU 6th FP), Royal Physiographic Society, Kock's Foundations, Memory of Lars Hierta's Foundation, Torsten och Ragnar Söderberg's Foundations, Foundation Olle Engkvist Byggmästare, King Gustaf V's and Queen Victoria's Stiftelse, Swedish Brain Foundation, and Parkinson's Disease Society UK.

References (301)

  • J.C. Bensadoun et al.

    Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF

    Exp. Neurol.

    (2000)
  • M.M. Bespalov et al.

    GDNF family receptor complexes are emerging drug targets

    Trends Pharmacol. Sci.

    (2007)
  • K.D. Bingaman et al.

    The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies

    Prog. Brain Res.

    (2000)
  • A. Bjorklund et al.

    Dopamine neuron systems in the brain: an update

    Trends Neurosci.

    (2007)
  • A. Bjorklund et al.

    Neural transplantation for the treatment of Parkinson's disease

    Lancet Neurol.

    (2003)
  • P.J. Blanchet et al.

    Complications of a trophic xenotransplant approach in parkinsonian monkeys

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (2003)
  • M. Brizard et al.

    Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease

    Neurobiol. Dis.

    (2006)
  • P. Brundin et al.

    Survival and function of dissociated rat dopamine neurons grafted at different developmental stages or after being cultured in vitro

    Brain Res.

    (1988)
  • P. Brundin et al.

    The neurobiology of cell transplantation in Parkinson's disease

    Clin. Neurosci. Res.

    (2001)
  • P. Brundin et al.

    Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival

    Brain Res.

    (1985)
  • G. Cacalano et al.

    GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney

    Neuron

    (1998)
  • M. Carlen et al.

    Functional integration of adult-born neurons

    Curr. Biol.

    (2002)
  • T. Carlsson et al.

    Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia

    Neurobiol. Dis.

    (2006)
  • M.K. Carpenter et al.

    Enrichment of neurons and neural precursors from human embryonic stem cells

    Exp. Neurol.

    (2001)
  • S.O. Castillo et al.

    Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene

    Mol. Cell. Neurosci.

    (1998)
  • D.S. Castro et al.

    Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells

    J. Biol. Chem.

    (2001)
  • M.A. Cenci

    Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia

    Trends Neurosci.

    (2007)
  • Y. Chen et al.

    Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor

    Exp. Neurol.

    (2005)
  • D.L. Choi-Lundberg et al.

    Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor

    Exp. Neurol.

    (1998)
  • Y. Chu et al.

    Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?

    Neurobiol. Dis.

    (2007)
  • E.D. Clarkson et al.

    Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats

    Brain Res.

    (1998)
  • B. Connor et al.

    The role of neuronal growth factors in neurodegenerative disorders of the human brain

    Brain Res. Brain Res. Rev.

    (1998)
  • J. Cowden et al.

    Ventral dominance governs sequential patterns of gene expression across the dorsal–ventral axis of the neuroectoderm in the Drosophila embryo

    Dev. Biol.

    (2003)
  • L.A. Cunningham et al.

    Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease

    Exp. Neurol.

    (2002)
  • G.P. Dietz et al.

    Application of a blood–brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease

    Brain Res.

    (2006)
  • G. Di Gioacchino et al.

    Transdifferentiation of stem cells in pancreatic cells: state of the art

    Transplant. Proc.

    (2005)
  • F. Doetsch et al.

    Subventricular zone astrocytes are neural stem cells in the adult mammalian brain

    Cell

    (1999)
  • G. Doucet et al.

    Host afferents into intrastriatal transplants of fetal ventral mesencephalon

    Exp. Neurol.

    (1989)
  • Y. Echelard et al.

    Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity

    Cell

    (1993)
  • B.F. El-Khodor et al.

    Ectopic expression of cell cycle markers in models of induced programmed cell death in dopamine neurons of the rat substantia nigra pars compacta

    Exp. Neurol.

    (2003)
  • V. Failli et al.

    Expression of the LIM-homeodomain gene Lmx1a (dreher) during development of the mouse nervous system

    Mech. Dev.

    (2002)
  • L.J. Fisher et al.

    Electrophysiological characteristics of cells within mesencephalon suspension grafts

    Neuroscience

    (1991)
  • J.E. Ahlskog et al.

    Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

    Mov. Disord.

    (2001)
  • P. Akerud et al.

    Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease

    J. Neurosci.

    (2001)
  • C. Allison

    Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma

    Issues Emerg. Health Technol.

    (2007)
  • M. Alvarez-Dolado et al.

    Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes

    Nature

    (2003)
  • M. Aoi et al.

    GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration

    Acta Neurochir. (Wien)

    (2000)
  • M. Aoi et al.

    Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system

    Neurol. Res.

    (2000)
  • T. Barberi et al.

    Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice

    Nat. Biotechnol.

    (2003)
  • K.D. Beck et al.

    Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

    Nature

    (1995)
  • Cited by (127)

    • Comparative review of adult midbrain and striatum neurogenesis with classical neurogenesis

      2018, Neuroscience Research
      Citation Excerpt :

      A number of signalling pathways have been identified to play key roles in development of midbrain DA neurons. Development of ventral mesencephalon (VM) depends on appropriate gene expression patterns controlled by signals from two centres: 1) the floor plate of the midbrain; and 2) the isthmus organiser, which is located at the junction of midbrain and hindbrain (Hegarty et al., 2013; Deierborg et al., 2008). Differentiation of mature DA cells from uncommitted progenitor cells in mouse is summarised in five stages: 1) Regional specification stage (E7–8): at the end of gastrulation (E7–7.5), the two homeobox-containing transcription factors, orthodenticle homeobox 2 (Otx2) and Gastrulation Brain Homeobox 2 (Gbx2) start to be expressed by fore-and midbrain (Simon et al., 2003; Simeone et al., 1992) and anterior hind brain, respectively (Simeone, 2000; Wassarman et al., 1997).

    • Evidence of functional duplicity of Nestin expression in the adult mouse midbrain

      2017, Stem Cell Research
      Citation Excerpt :

      These cells had a migrating morphology suggestive of migration from the Aq ventrally. Developmental DA neurogenesis follows a similar trajectory (Deierborg et al., 2008), which initially led us to think it might be recapitulated in the adult. However, β-gal + or eYFP + cells in the ventral midline were the same distance away from Aq along the dorso-ventral axis with time following tamoxifen, indicating they are not moving ventrally (or dorsally).

    • Aging of cerebral white matter

      2017, Ageing Research Reviews
    View all citing articles on Scopus
    View full text